Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment

References

• Xu J, Zheng Q, Cheng X, et al. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology. 2021;19(1):355. doi:10.1186/s12951-021-01101-1
   PubMed Web of Science ®Google Scholar
• Abuduwaili W, Wang X, Huang AT, et al. Iridium complex-loaded sorafenib nanocomposites for synergistic chemo-photodynamic therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2022;14(33):37356–37368. doi:10.1021/acsami.2c07247
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Y, Choi W, et al. Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chem Soc Rev. 2021;50(16):9152–9201. doi:10.1039/d0cs01370f
   PubMed Web of Science ®Google Scholar
• Li SG, Shi QW, Yuan LY, et al. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2018;37(1):51. doi:10.1186/s13046-018-0698-2
   PubMedGoogle Scholar
• Zhang YQ, Shen Y, Liao MM, et al. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. Nanomedicine. 2019;15(1):86–97. doi:10.1016/j.nano.2018.09.002
   PubMed Web of Science ®Google Scholar
• Ling D, Xia H, Park W, et al. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano. 2014;8(8):8027–8039. doi:10.1021/nn502074x
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu X, Zhang P, et al. Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma. Acta Pharm Sin B. 2019;9(5):1050–1060. doi:10.1016/j.apsb.2019.06.001
   PubMed Web of Science ®Google Scholar
• Sun R, Dai J, Ling M, Yu L, Yu Z, Tang L. Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine. J Nanobiotechnology. 2022;20(1):194. doi:10.1186/s12951-022-01389-7
   PubMed Web of Science ®Google Scholar
• Alsaied OA, Sangwan V, Banerjee S, et al. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 2014;156(2):270–279. doi:10.1016/j.surg.2014.04.055
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gu Y, Qi F, et al. Engineering adipocytes for targeting delivery of triptolide derivative and Ce6 for malignant melanoma cytotoxic-PDT synergistic strategy[J]. Mater Design. 2023;228:111860 doi:10.1016/j.matdes.2023.111860
   Web of Science ®Google Scholar
• Yu L, Wang Z, Mo Z, et al. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sin B. 2021;11(7):2004–2015. doi:10.1016/j.apsb.2021.02.001
   PubMed Web of Science ®Google Scholar
• Aghizadeh B, Taranejoo S, Monemian SA, et al. Classification of stimuli-responsive polymers as anticancer drug delivery systems. Drug Deliv. 2015;22(2):145–155. doi:10.3109/10717544.2014.887157
   PubMed Web of Science ®Google Scholar
• Alshememry AK, El-Tokhy SS, Unsworth LD. Using properties of tumor microenvironments for controlling local, on-demand delivery from biopolymer-based nanocarriers. Curr Pharm Des. 2017;23(35):5358–5391. doi:10.2174/1381612823666170522100545
   PubMed Web of Science ®Google Scholar
• Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9(1):e2103836. doi:10.1002/advs.202103836
   Web of Science ®Google Scholar
• Shi J, Ren Y, Ma J, et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. J Nanobiotechnology. 2021;19(1):188. doi:10.1186/s12951-021-00934-0
   PubMed Web of Science ®Google Scholar
• Wu Y, Li J, Zhong X, et al. A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy. Asian J Pharm Sci. 2022;17(2):206–218. doi:10.1016/j.ajps.2021.12.003
   PubMed Web of Science ®Google Scholar
• Liu N, Wu L, Zuo W, et al. pH/Thermal-sensitive nanoplatform capable of on-demand specific release to potentiate drug delivery and combinational Hyperthermia/Chemo/Chemodynamic Therapy. ACS Appl Mater Interfaces. 2022;14(26):29668–29678. doi:10.1021/acsami.2c09685
   PubMedGoogle Scholar
• Wang H, Gao Z, Jiao D, et al. A microenvironment dual-responsive nano-drug equipped with PD-L1 blocking peptide triggers immunogenic pyroptosis for prostate cancer self-synergistic immunotherapy. Adv Funct Mater. 2023;33(16):2214499. doi:10.1002/adfm.202214499
   Web of Science ®Google Scholar
• Zhang S, Guo N, Wan G, et al. pH and redox dual-responsive nanoparticles based on disulfide-containing poly (β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. J Nanobiotechnology. 2019;17(1):109. doi:10.1186/s12951-019-0540-9
   PubMed Web of Science ®Google Scholar
• Yin TJ, Wang YY, Chu XX, et al. Free adriamycin-loaded pH/reduction dual-responsive hyaluronic acid-adriamycin prodrug micelles for efficient cancer therapy. ACS Appl Mater Interfaces. 2018;10(42):35693–35704. doi:10.1021/acsami.8b09342
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Tian H, et al. Redox-responsive and dual-targeting hyaluronic acid-methotrexate prodrug self-assembling nanoparticles for enhancing intracellular drug self-delivery. Mol Pharm. 2019;16(07):3133–3144. doi:10.1021/acs.molpharmaceut.9b00359
   PubMedGoogle Scholar
• Feng Y, Xie X, Zhang H, et al. Multistage-responsive nanovehicle to improve tumor penetration for dual-modality imaging-guided photodynamic-immunotherapy. Biomaterials. 2021;275:120990. doi:10.1016/j.biomaterials.2021.120990
   PubMed Web of Science ®Google Scholar
• Lin C, He H, Zhang Y, et al. Acetaldehyde-modified-cystine functionalized ZrMOFs for pH/GSH dual-responsive drug delivery and selective visualization of GSH in living cells. RSC Adv. 2020;10(6):3084–3091. doi:10.1039/C9RA05741B
   PubMed Web of Science ®Google Scholar
• Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22(5):280–297. doi:10.1038/s41568-021-00435-0
   PubMed Web of Science ®Google Scholar
• Wang S, Yu K, Yu Z, et al. Targeting self-enhanced ROS-responsive artesunatum prodrug nanoassembly potentiates gemcitabine activity by down-regulating CDA expression in cervical cancer[J]. Chinese Chem Lett. 2023;34(7):108184 doi:10.1016/j.cclet.2023.108184
   Web of Science ®Google Scholar
• Niu W, Wang J, Wang Q, Shen J. Celastrol loaded nanoparticles with ROS-response and ros-inducer for the treatment of ovarian cancer. Front Chem. 2020;8:574614. doi:10.3389/fchem.2020.574614
   PubMed Web of Science ®Google Scholar
• Zhu D, Zhang Q, Chen Y, et al. Mechanochemical preparation of triptolide-loaded self-micelle solid dispersion with enhanced oral bioavailability and improved anti-tumor activity. Drug Deliv. 2022;29(1):1398–1408. doi:10.1080/10717544.2022.2069879
   PubMed Web of Science ®Google Scholar
• Kim ST, Kim SY, Lee J, et al. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer. 2018;18(1):1103. doi:10.1186/s12885-018-4995-0
   PubMedGoogle Scholar
• Wei YM, Wang YH, Xue HQ, Luan ZH, Liu BW, Ren JH. Triptolide, A Potential Autophagy Modulator. Chin J Integr Med. 2019;25(3):233–240 doi:10.1007/s11655-018-2847-z
   PubMed Web of Science ®Google Scholar
• Xi C, Peng S, Wu Z, Zhou Q, Zhou J. Toxicity of triptolide and the molecular mechanisms involved. Biomed Pharmacother. 2017;90:531–541. doi:10.1016/j.biopha.2017.04.003
   PubMed Web of Science ®Google Scholar
• Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnology. 2021;19(1):360. doi:10.1186/s12951-021-01095-w
   PubMed Web of Science ®Google Scholar
• Xing W, Liu G, Zhang Y, Zhang T, Lou H, Fan P. Selective antitumor effect and lower toxicity of mitochondrion-targeting derivatization of triptolide. J Med Chem. 2024;67(2):1093–1114. doi:10.1021/acs.jmedchem.3c01508
   PubMed Web of Science ®Google Scholar
• Ruiz-González R, Milán P, Bresolí-Obach R, et al. Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells. Cancers. 2017;9(2):18. doi:10.3390/cancers9020018
   PubMed Web of Science ®Google Scholar
• Zhou Z, Song J, Nie L, Chen X. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chem Soc Rev. 2016;45(23):6597–6626. doi:10.1039/c6cs00271d
   PubMed Web of Science ®Google Scholar
• Lovell JF, Liu TW, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev. 2010;110(5):2839–2857. doi:10.1021/cr900236h
   PubMed Web of Science ®Google Scholar
• Kessel D. Photodynamic therapy: apoptosis, paraptosis and beyond. Apoptosis. 2020;25(09–10):611–615. doi:10.1007/s10495-020-01634-0
   PubMed Web of Science ®Google Scholar